Kura Oncology, Inc. filed its quarterly report on Form 10-Q with the SEC on August 12, 2026, covering the three- and six-month periods ended June 30, 2026, disclosing a net loss of $68.3 million for the second quarter and $141.7 million for the first half of the year.

Key Highlights

  • Q2 2026 net loss: $68,327 thousand ($0.77 per share, basic and diluted), compared to $66,122 thousand ($0.75 per share) in Q2 2025.
  • Q2 2026 total revenue: $20,874 thousand, including $9,122 thousand in product revenue, net, and $11,752 thousand in collaboration revenue.
  • Six-month net loss: $141,660 thousand ($1.60 per share), versus $123,551 thousand ($1.41 per share) for the first half of 2025.
  • Cash and short-term investments: $70,242 thousand in cash and cash equivalents plus $448,783 thousand in short-term investments as of June 30, 2026.
  • Total stockholders' equity: Declined to $48,431 thousand as of June 30, 2026, from $174,135 thousand as of December 31, 2025.
  • Accumulated deficit: $1,315,748 thousand as of June 30, 2026.
  • Shares outstanding: 88,960,619 shares of common stock as of August 7, 2026.

Kura Oncology's Second-Quarter 2026 Revenue, Losses, and Balance Sheet Position

According to the filing, Kura Oncology (NASDAQ:KURA) generated total revenue of $20,874 thousand in the three months ended June 30, 2026, compared to $15,288 thousand in the same period of 2025. The company disclosed that $9,122 thousand of Q2 2026 revenue came from product revenue, net, a line that did not exist in Q2 2025, while collaboration revenue declined to $11,752 thousand from $15,288 thousand year over year. For the six months ended June 30, 2026, total revenue was $39,139 thousand versus $29,396 thousand for the same period in 2025.

Total operating expenses for Q2 2026 were $93,884 thousand, up from $87,954 thousand in Q2 2025, driven primarily by research and development expenses of $61,891 thousand and selling, general and administrative expenses of $31,750 thousand. Cost of product sales was $243 thousand for the quarter. The resulting loss from operations was $73,010 thousand for Q2 2026. Net cash used in operating activities was $148,403 thousand for the six months ended June 30, 2026, compared to $100,704 thousand for the same period in 2025, according to the filing.

The condensed balance sheet reported total assets of $587,791 thousand and total liabilities of $539,360 thousand as of June 30, 2026. Long-term contract liabilities stood at $398,604 thousand. Share-based compensation expense for the six-month period was $16,625 thousand, the filing disclosed. The accumulated deficit grew from $1,174,088 thousand at December 31, 2025, to $1,315,748 thousand at June 30, 2026.

What Was Disclosed

Kura Oncology's 10-Q for the quarter ended June 30, 2026, reported a net loss of $68,327 thousand for Q2 and $141,660 thousand for the first half of the year, alongside the initiation of product revenue and a reduction in total stockholders' equity to $48,431 thousand.